Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | HPGD | P15428 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7399750 | 0.80 | ALDH1A1 (0.71) | ALDH1A1HPGDKDM4EHSD17B10KMT2A | |
| SCHEMBL14919610 | 0.77 | ALDH1A1 (0.78) | ALDH1A1HPGDKDM4EHSD17B10KMT2A | |
| SCHEMBL14919790 | 0.75 | ALDH1A1 (0.61) | ALDH1A1HPGDKDM4EHSD17B10KMT2A | |
| SCHEMBL14919675 | 0.74 | KMT2A (0.56) | ALDH1A1HPGDKDM4EHSD17B10KMT2A | |
| SCHEMBL14919711 | 0.73 | ALDH1A1 (1.00) | ALDH1A1HPGDKDM4EHSD17B10KMT2A | |
| SCHEMBL14919673 | 0.73 | KMT2A (0.71) | ALDH1A1HPGDKDM4EHSD17B10KMT2A | |
| SCHEMBL14919781 | 0.73 | KMT2A (0.70) | ALDH1A1HPGDKDM4EHSD17B10KMT2A | |
| SCHEMBL14919481 | 0.73 | POLB (0.68) | ALDH1A1HPGDKDM4EHSD17B10KMT2A | |
| SCHEMBL14919776 | 0.73 | ALDH1A1 (0.78) | ALDH1A1HPGDKDM4EHSD17B10KMT2A | |
| SCHEMBL14919764 | 0.73 | ALDH1A1 (0.73) | ALDH1A1HPGDKDM4EHSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0912519-A1 | QUINOLINE SULFONAMIDES AS TNF INHIBITORS AND AS PDE-IV INHIBITORS | Darwin Discovery Limited (GB) | 1999-05-06 | — | — | EP | claimed |
| US-5834485-A | Quinoline sulfonamides and their therapeutic use | CHIROSCIENCE LIMITED (GB) | 1998-11-10 | — | — | US | claimed |
| WO-1997044322-A1 | QUINOLINE SULFONAMIDES AS TNF INHIBITORS AND AS PDE-IV INHIBITORS | DARWIN DISCOVERY LIMITED (GB) | 1997-11-27 | — | — | WO | claimed |
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| EP-0912519-A1 | QUINOLINE SULFONAMIDES AS TNF INHIBITORS AND AS PDE-IV INHIBITORS | Darwin Discovery Limited (GB) | 1999-05-06 | — | — | EP | disclosed |
| US-5834485-A | Quinoline sulfonamides and their therapeutic use | CHIROSCIENCE LIMITED (GB) | 1998-11-10 | — | — | US | disclosed |
| WO-1997044322-A1 | QUINOLINE SULFONAMIDES AS TNF INHIBITORS AND AS PDE-IV INHIBITORS | DARWIN DISCOVERY LIMITED (GB) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | ALDH1A1 2348/4885HPGD 1094/4885KDM4E 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.